As pandemic enters new phase, AstraZeneca looks for vaccine profits

12 November 2021
astrazeneca_big

Spying  eye-watering profits at rival coronavirus vaccine developers, Vaxzevria manufacturer AstraZeneca (LSE: AZN) has taken a step towards boosting revenues with its first for-profits deal.

The announcement comes as the company reports revenue growth of 50% in the third quarter of 2021, at $9.9 billion, around $1 billion of which came from COVID vaccine sales.

The revenue result is a little higher than most analysts had been expecting. Following Generally Accepted Accounting Principles (GAAP), there was a loss per share in the third quarter of $1.10.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical